Search
CG Oncology Inc
CGONAdd to Watchlist
71.050USD
-2.680-3.63%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
6.25BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-3.63%
5 Days
+7.25%
1 Month
+14.06%
6 Months
+78.25%
Year to Date
+71.12%
1 Year
+173.80%
Key Figures
75.070Open
76.600High
1.41MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.60%Turnover Ratio
73.730Prev. Close
70.545Low
77.41MTurnover
LossP/E Static
5.73P/B
0.00%Div Yield TTM
-20.04%ROA
75.50052wk High
0.72Volume Ratio
-88.04MNet Profit
88.01MShares
-2.3427EPS TTM
--Beta
-20.79%ROE
23.65052wk Low
8.21%Amplitude
-173.50%Gross Margin
6.25BMarket Cap
7.05Reward/Risk
3.47%Risk Rate
TradingKey Stock Score of CG Oncology Inc
Currency: USD Updated: 2026-06-29Key Insights
CG Oncology Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 26 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 89.85.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CG Oncology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
CG Oncology Inc Highlights
StrengthsRisks
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 1880.39% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 4.04M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 4.04M.
Undervalued
The company’s latest PE is -31.47, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 92.88M shares, decreasing 6.79% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 444.57K shares of this stock.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
89.846
Target Price
+24.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CG Oncology Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CG Oncology Inc Info
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Ticker SymbolCGON
CompanyCG Oncology Inc
CEOKuan (Arthur)
Websitehttps://www.cgoncology.com/
Related Instruments
-2.50%
-1.79%
-0.56%
-1.22%
-0.73%
-0.57%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52196.300
+43.100 (+0.08%)
30224.600
+516.900 (+1.74%)
7482.400
+50.200 (+0.68%)
15595.000
+144.000 (+0.93%)
70856.000
+382.000 (+0.54%)
6327.000
+71.200 (+1.14%)
69.921
-0.395 (-0.56%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4007.280
-8.310 (-0.21%)
FAQs
What is the current price of CG Oncology Inc (CGON)?
The current price of CG Oncology Inc (CGON) is 73.73.
What is the symbol of CG Oncology Inc?
The ticker symbol of CG Oncology Inc is CGON.
What is the 52-week high of CG Oncology Inc?
The 52-week high of CG Oncology Inc is 75.50.
What is the 52-week low of CG Oncology Inc?
The 52-week low of CG Oncology Inc is 23.65.
What is the market capitalization of CG Oncology Inc?
The market capitalization of CG Oncology Inc is 6.50B.
Is CG Oncology Inc (CGON) currently rated as Buy, Hold, or Sell?
According to analysts, CG Oncology Inc (CGON) has an overall rating of Buy, with a price target of 89.85.
What is the Earnings Per Share (EPS TTM) of CG Oncology Inc (CGON)?
The Earnings Per Share (EPS TTM) of CG Oncology Inc (CGON) is -2.08.
